JPWO2019146759A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019146759A5 JPWO2019146759A5 JP2019567188A JP2019567188A JPWO2019146759A5 JP WO2019146759 A5 JPWO2019146759 A5 JP WO2019146759A5 JP 2019567188 A JP2019567188 A JP 2019567188A JP 2019567188 A JP2019567188 A JP 2019567188A JP WO2019146759 A5 JPWO2019146759 A5 JP WO2019146759A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- chrnb2
- antibody
- molecular
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022134818A JP7621664B2 (ja) | 2018-01-26 | 2022-08-26 | 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018011937 | 2018-01-26 | ||
| JP2018011937 | 2018-01-26 | ||
| PCT/JP2019/002504 WO2019146759A1 (ja) | 2018-01-26 | 2019-01-25 | 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022134818A Division JP7621664B2 (ja) | 2018-01-26 | 2022-08-26 | 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2019146759A1 JPWO2019146759A1 (ja) | 2021-03-18 |
| JPWO2019146759A5 true JPWO2019146759A5 (https=) | 2022-02-24 |
| JP7312451B2 JP7312451B2 (ja) | 2023-07-21 |
Family
ID=67395021
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019567188A Active JP7312451B2 (ja) | 2018-01-26 | 2019-01-25 | 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法 |
| JP2022134818A Active JP7621664B2 (ja) | 2018-01-26 | 2022-08-26 | 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022134818A Active JP7621664B2 (ja) | 2018-01-26 | 2022-08-26 | 受容体タンパク質を標的とする治療薬、検査薬、受容体タンパク質に結合する抗体、及び分子標的薬のスクリーニング方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11773169B2 (https=) |
| EP (2) | EP3744346A4 (https=) |
| JP (2) | JP7312451B2 (https=) |
| CN (2) | CN112739380A (https=) |
| WO (1) | WO2019146759A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114231635B (zh) * | 2021-12-31 | 2023-03-31 | 博尔诚（北京）科技有限公司 | 用于肺癌筛查的标志物、探针组合物及其应用 |
| CN118243808B (zh) * | 2024-02-05 | 2024-12-31 | 石家庄四药有限公司 | 一种np-01中有关物质的检测方法 |
| EP4635983A1 (en) | 2024-04-15 | 2025-10-22 | Ymmunobio AG | A novel antibody binding specifically to nptxr and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ749100A0 (en) | 2000-05-12 | 2000-06-08 | Bionomics Limited | New epilespy gene |
| US20050037445A1 (en) * | 2001-06-25 | 2005-02-17 | Poulsen Hans Skovgaard | Oncology drug innovation |
| JP2005501536A (ja) | 2001-07-18 | 2005-01-20 | バイオノミックス リミテッド | イオンチャネルにおける変異 |
| CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| US20090232893A1 (en) * | 2007-05-22 | 2009-09-17 | Bader Andreas G | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| RU2010111120A (ru) | 2007-08-24 | 2011-09-27 | Онкотерапи Сайенс, Инк. (Jp) | Eb13, dlx5, nptx1 и cdkn3 в качестве генов-мишеней для терапии и диагностики рака легкого |
| US20090123940A1 (en) | 2007-10-12 | 2009-05-14 | The Johns Hopkins University | Molecules involved in synaptogenesis and uses therefor |
| CN102719522A (zh) * | 2011-03-31 | 2012-10-10 | 上海市肿瘤研究所 | 乙酰胆碱酯酶基因启动子用于抗肝癌药物的筛选 |
| WO2012153492A1 (en) | 2011-05-06 | 2012-11-15 | Oncotherapy Science, Inc. | Nptx2 as tumor marker and therapeutic target for cancer |
| JP2017511342A (ja) | 2014-04-04 | 2017-04-20 | オンコメッド ファーマシューティカルズ インコーポレイテッド | 胃がんの処置 |
-
2019
- 2019-01-25 JP JP2019567188A patent/JP7312451B2/ja active Active
- 2019-01-25 CN CN201980022443.1A patent/CN112739380A/zh active Pending
- 2019-01-25 EP EP19744055.5A patent/EP3744346A4/en active Pending
- 2019-01-25 WO PCT/JP2019/002504 patent/WO2019146759A1/ja not_active Ceased
- 2019-01-25 US US16/964,236 patent/US11773169B2/en active Active
- 2019-01-25 EP EP22196119.6A patent/EP4169532A1/en active Pending
- 2019-01-25 CN CN202211167212.XA patent/CN116059349A/zh active Pending
-
2022
- 2022-08-26 JP JP2022134818A patent/JP7621664B2/ja active Active
- 2022-09-15 US US17/932,450 patent/US12129301B2/en active Active
-
2023
- 2023-08-03 US US18/364,644 patent/US12098205B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress | |
| JP6599334B2 (ja) | 血中循環腫瘍細胞に関する方法およびアッセイ | |
| Adam et al. | miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy | |
| Seaman et al. | Genes that distinguish physiological and pathological angiogenesis | |
| Taniuchi et al. | KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells | |
| Sommer et al. | The RNA-binding protein La contributes to cell proliferation and CCND1 expression | |
| De Luca et al. | Enhanced expression of LINE-1-encoded ORF2 protein in early stages of colon and prostate transformation | |
| Rangel et al. | Identification of new tumor suppressor genes in triple-negative breast cancer | |
| CN103328500B (zh) | 用于癌症的诊断和治疗的方法和化合物 | |
| Gao et al. | A novel lncRNA MTAR1 promotes cancer development through IGF2BPs mediated post-transcriptional regulation of c-MYC | |
| JP7376873B2 (ja) | がん促進因子発現抑制剤、その有効成分のスクリーニング方法、該方法に有用な発現カセット、診断薬、及び診断方法 | |
| Sun et al. | RBMS1 coordinates with the m6A reader YTHDF1 to promote NSCLC metastasis through stimulating S100P translation | |
| JPWO2019146759A5 (https=) | ||
| CN112739826A (zh) | 抗体-药物缀合物的敏感性标志物 | |
| JP7171712B2 (ja) | プロスタグランジンＥ依存性腫瘍の層別化のためのバイオマーカーとしてのｍｉＲＮＡ－５７４－５ｐ | |
| US9644026B2 (en) | Antibody against mutant α-actinin-4 | |
| US9574240B2 (en) | Gene amplification of coactivator CoAA and uses thereof | |
| Ma et al. | LSM6 promotes cell proliferation and migration regulated by HMGB1 in laryngeal squamous cell carcinoma | |
| CN114790457A (zh) | circB3GALNT2在结直肠癌转移预测和治疗中的应用 | |
| Banerjee | Diverse roles of RNA-protein interactions: From viral antagonism to mammalian development | |
| JP6462632B2 (ja) | 変異型α−アクチニン−４に対する抗体 | |
| KR101646746B1 (ko) | 자궁경부암의 유도에 관여하는 악티닌―４의 약제학적 용도 | |
| KR20120009903A (ko) | 암 진단 키트 및 암 예방 또는 치료용 약제학적 조성물 | |
| CN102435750A (zh) | 一种筛选治疗或预防癌症的药物的方法 | |
| CN102411058A (zh) | 一种筛选治疗或预防癌症的药物的方法 |